| INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors Q Li, B Jiang, J Guo, H Shao, IS Del Priore, Q Chang, R Kudo, Z Li, ... Cancer discovery 12 (2), 356-371, 2022 | 83 | 2022 |
| Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling M Fan, W Lu, J Che, NP Kwiatkowski, Y Gao, HS Seo, SB Ficarro, ... Elife 11, e78810, 2022 | 25 | 2022 |
| The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve, KM Hamel, ... Nature 622 (7984), 850-862, 2023 | 22 | 2023 |
| Virtual screening for small-molecule pathway regulators by image-profile matching MH Rohban, AM Fuller, C Tan, JT Goldstein, D Syangtan, A Gutnick, ... Cell systems 13 (9), 724-736. e9, 2022 | 20 | 2022 |
| Systematic identification of biomarker-driven drug combinations to overcome resistance MG Rees, L Brenan, M do Carmo, P Duggan, B Bajrami, M Arciprete, ... Nature chemical biology 18 (6), 615-624, 2022 | 12 | 2022 |
| Structure-based design of Y-shaped covalent TEAD inhibitors W Lu, M Fan, W Ji, J Tse, I You, SB Ficarro, I Tavares, J Che, AY Kim, ... Journal of medicinal chemistry 66 (7), 4617-4632, 2023 | 7 | 2023 |
| Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation I You, KA Donovan, NM Krupnick, AS Boghossian, MG Rees, MM Ronan, ... Cell chemical biology 29 (11), 1630-1638. e7, 2022 | 7 | 2022 |
| Inflammatory Conditions During Pregnancy and Risk of Autism and Other Neurodevelopmental Disorders LA Croen, JL Ames, Y Qian, S Alexeeff, P Ashwood, EP Gunderson, ... Biological Psychiatry Global Open Science 4 (1), 39-50, 2024 | 4 | 2024 |
| Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunity A Iracheta-Vellve, H Ebrahimi-Nik, TR Davis, KE Olander, SY Kim, ... Cancer Research 82 (12_Supplement), 606-606, 2022 | 4 | 2022 |
| Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers M Payton, B Belmontes, K Hanestad, J Moriguchi, K Chen, JD McCarter, ... Nature Cancer 5 (1), 66-84, 2024 | 3 | 2024 |
| CDK9 inhibition is selective for transcriptionally addicted tumors harboring MYC genomic amplifications MA Day, ND Obholzer, A Pandey, T Chen, T Liang, RA Villagomez, ... Cancer Research 81 (13_Supplement), 1141-1141, 2021 | 2 | 2021 |
| Genetic dependencies associated with transcription factor activities in human cancer cell lines V Thatikonda, V Supper, MC Ravichandran, JJ Lipp, AS Boghossian, ... bioRxiv, 2023.02. 23.529701, 2023 | 1 | 2023 |
| 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress ML Calbert, G Chandramouly, CM Adams, M Saez-Ayala, T Kent, M Tyagi, ... Molecular Cancer Therapeutics, OF1-OF17, 2024 | | 2024 |
| Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis P Pichavaram, CM Jablonowski, J Fang, AM Fleming, HJ Gil, ... Molecular Cancer Therapeutics, OF1-OF14, 2024 | | 2024 |
| Abstract A092: Determinants of sensitivity to BI KRASmulti inhibitor using high-throughput in-vitro drug screens F Schischlik, A Tedeschi, D Rudolph, D Gerlach, B Wilding, M Treu, ... Molecular Cancer Therapeutics 22 (12_Supplement), A092-A092, 2023 | | 2023 |
| The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies A Pandey, LA Carvajal, AS Boghossian, MG Rees, MM Ronan, JA Roth, ... Blood 142, 2259, 2023 | | 2023 |
| 1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity H Ebrahimi-Nik, CK Baumgartner, A Iracheta-Vellve, KM Hamel, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | | 2023 |
| Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunity H Ebrahimi-Nik, A Iracheta-Vellve, KE Olander, TRG Davis, SY Kim, ... Cancer Immunology Research 10 (12_Supplement), A41-A41, 2022 | | 2022 |
| Discovery and preclinical characterization of novel small molecule inhibitors of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers. J Sun, B Belmontes, J Moriguchi, G Chung, K Chen, JD McCarter, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| Abstract LB202: Discovery and preclinical characterization of novel small molecule inhibitors of kinesin KIF18A motor protein with potent activity against chromosomally … J Sun, B Belmontes, J Moriguchi, G Chung, K Chen, JD McCarter, ... Cancer Research 82 (12_Supplement), LB202-LB202, 2022 | | 2022 |
